CNTA Stock Price, Centessa Pharmaceuticals Limited Quote, Chart

Market Summary

USD8.98+0.03

Delayedas of 17 May 2024, 02:09 pm

0.34%

CNTA Stock Price

View Fullscreen

CNTA RSI Chart

CNTA Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-7.31

Price/Sales (Trailing)

147.64

EV/EBITDA

-6.36

Price/Free Cashflow

-6.75

CNTA Price/Sales (Trailing)

CNTA Profitability

EBT Margin

-2388.28%

Return on Equity

-64.33%

Return on Assets

-42.18%

Free Cashflow Yield

-14.81%

CNTA Fundamentals

CNTA Revenue

Revenue (TTM)

6.9M

CNTA Earnings

Earnings (TTM)

-138.4M

Earnings Growth (Yr)

24.98%

Earnings Growth (Qtr)

-3.28%

Breaking Down CNTA Revenue

52 Week Range

3.969.06

(Low)(High)

Last 7 days

-6.2%

Last 30 days

-18.8%

Last 90 days

-23.7%

Trailing 12 Months

91.9%

How does CNTA drawdown profile look like?

CNTA Financial Health

Current Ratio

10.37

Debt/Equity

0.36

Debt/Cashflow

-1.95

CNTA Investor Care

Shares Dilution (1Y)

18.78%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	6.9M
2022	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Centessa Pharmaceuticals Limited

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	hussain iqbal j	sold (taxes)	-84,976	11.3	-7,520	general counsel
Mar 31, 2024	chao david m	sold (taxes)	-117,350	11.3	-10,385	chief administrative officer
Mar 31, 2024	weinhoff gregory m	sold (taxes)	-132,685	11.3	-11,742	chief financial officer
Mar 31, 2024	saha saurabh	sold (taxes)	-409,772	11.3	-36,263	chief executive officer
Mar 31, 2024	bush tia l	sold (taxes)	-72,534	11.3	-6,419	chief technology & quality ofc
Mar 25, 2024	anderson karen m.	sold	-607,960	11.8835	-51,160	chief people officer
Mar 25, 2024	anderson karen m.	acquired	177,252	3.93892	45,000	chief people officer
Feb 01, 2024	bush tia l	sold (taxes)	-31,629	8.19	-3,862	chief quality officer
Feb 01, 2024	hussain iqbal j	acquired	-	-	42,500	general counsel
Feb 01, 2024	anderson karen m.	acquired	-	-	31,250	chief people officer

Which funds bought or sold CNTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ADAR1 Capital Management, LLC	new	-	2,337,470	2,337,470	0.53%
May 15, 2024	Cubist Systematic Strategies, LLC	added	1,405	782,083	820,482	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-100,526	-	-%
May 15, 2024	Woodline Partners LP	sold off	-100	-1,121,210	-	-%
May 15, 2024	5AM Venture Management, LLC	new	-	14,068,500	14,068,500	3.15%
May 15, 2024	Octagon Capital Advisors LP	unchanged	-	6,880,730	23,279,100	2.79%
May 15, 2024	Kynam Capital Management, LP	sold off	-100	-3,523,920	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-53.41	-271,662	530,738	-%
May 15, 2024	TCG Crossover Management, LLC	unchanged	-	6,816,330	23,061,200	1.82%
May 15, 2024	Lynx1 Capital Management LP	new	-	196,620	196,620	0.05%

Are Funds Buying or Selling CNTA?

Are funds buying CNTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CNTA

No. of Funds

Unveiling Centessa Pharmaceuticals Limited's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	5.8%	5,618,779	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	4.7%	4,624,752	SC 13G/A
Feb 09, 2023	janus henderson group plc	2.2%	2,114,519	SC 13G/A
Jan 31, 2023	medicxi growth i lp	4.2%	3,936,970	SC 13G/A
Nov 23, 2022	ecor1 capital, llc	5.5%	5,232,279	SC 13G
Jun 16, 2022	biotechnology value fund l p	4.0%	3,734,708	SC 13G
Feb 14, 2022	index ventures life vi (jersey) l.p.	10.9%	9,812,368	SC 13G
Feb 11, 2022	janus henderson group plc	6.4%	5,743,397	SC 13G
Feb 08, 2022	medicxi growth i lp	4.4%	3,936,970	SC 13G

Recent SEC filings of Centessa Pharmaceuticals Limited

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 09, 2024	ARS	ARS
May 09, 2024	DEF 14A	DEF 14A
Apr 26, 2024	PRE 14A	PRE 14A
Apr 25, 2024	424B5	Prospectus Filed
Apr 24, 2024	8-K	Current Report
Apr 23, 2024	424B5	Prospectus Filed
Apr 22, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Centessa Pharmaceuticals Limited)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Centessa Pharmaceuticals Limited News

Latest updates

Centessa Pharmaceuticals Limited Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4
S&GA Expenses	-10.6%	12,315,000	13,768,000
EBITDA Margin	-Infinity%	-24.14	-
Interest Expenses	16.7%	2,570,000	2,202,500
Income Taxes	276.0%	1,168,500	-664,000
Earnings Before Taxes	18.6%	-35,693,000	-43,837,000
EBT Margin	-Infinity%	-25.70	-
Net Income	14.7%	-36,837,000	-43,173,000
Net Income Margin	-Infinity%	-22.05	-
Free Cashflow	40.5%	-31,078,000	-52,216,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-8.9%	328	360	377	393	404	444	479	521	582	630	612	644	-
Current Assets	-9.7%	284	315	332	350	384	438	477	519	581	629	612	644	11.00
Cash Equivalents	-7.7%	118	128	171	145	260	394	445	484	544	595	579	614	7.00
Net PPE	-8.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	-
Liabilities	-8.9%	113	124	118	116	111	108	106	101	102	138	63.00	58.00	9.00
Current Liabilities	-30.3%	27.00	39.00	35.00	34.00	30.00	38.00	38.00	34.00	27.00	25.00	29.00	24.00	9.00
Long Term Debt	1.5%	77.00	76.00	74.00	73.00	72.00	70.00	68.00	67.00	75.00	76.00	-	-	-
LT Debt, Non Current	-100.0%	-	76.00	74.00	73.00	72.00	70.00	68.00	67.00	75.00	76.00	-	-	-
Shareholder's Equity	-8.9%	215	236	259	277	293	336	373	420	480	492	549	586	-
Retained Earnings	-5.1%	-790	-752	-716	-677	-652	-601	-558	-504	-440	-385	-324	-284	-9.22
Additional Paid-In Capital	1.7%	1,004	987	974	953	946	939	933	926	920	876	871	867	-
Shares Outstanding	1.6%	100	99.00	98.00	95.00	95.00	95.00	94.00	92.00	91.00	90.00	70.00	64.00	-
Float	-	-	-	-	311	-	-	-	241	-	-	-	1,073	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-20.1%	-37,286	-31,050	-37,392	-44,062	-47,838	-51,564	-39,088	-59,877	-50,017	-56,427	-33,170	-33,877	-11,635	-	-3,281	-1,895	-	-
Share Based Compensation	9.7%	8,154	7,430	7,559	7,213	7,190	6,617	7,027	5,603	5,718	4,758	4,133	3,229	2,731	-	91.00	92.00	-	-
Cashflow From Investing	191.7%	16,762	-18,275	48,706	-71,099	-86,336	-446	-16.00	-229	-240	-64.00	-48.00	-149	63,517	-	-	-	-	-
Cashflow From Financing	65.0%	10,493	6,361	14,744	12.00	-	89.00	224	70.00	74.00	74,429	-1,992	345,821	241,889	-	1,285	77.00	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CNTA Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 22,652	$ 32,826
General and administrative	13,438	16,051
Loss from operations	(36,090)	(48,877)
Interest income	2,591	2,531
Interest expense	(2,529)	(2,345)
Other (expense) income, net	(1,537)	(1,346)
Loss before income taxes	(37,565)	(50,037)
Income tax expense	481	677
Net loss	(38,046)	(50,714)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(25)	898
Unrealized gain on available for sale securities, net of tax	155	0
Other comprehensive income	130	898
Total comprehensive loss	$ (37,916)	$ (49,816)
Net loss per ordinary share - basic (in dollars per share)	$ (0.38)	$ (0.53)
Net loss per ordinary share - diluted (in dollars per share)	$ (0.38)	$ (0.53)
Weighted average ordinary shares outstanding - basic (in shares)	99,887,720	94,937,904
Weighted average ordinary shares outstanding - diluted (in shares)	99,887,720	94,937,904

CNTA Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 118,218	$ 128,030
Short-term investments	111,959	128,519
Tax incentive receivable	36,292	37,818
Prepaid expenses and other current assets	18,007	20,725
Total current assets	284,476	315,092
Property and equipment, net	952	1,039
Operating lease right-of-use assets	11,694	11,914
Deferred tax asset	29,166	29,647
Other, net	1,883	2,554
Total assets	328,171	360,246
Current liabilities:
Accounts payable	7,499	11,815
Accrued expenses and other current liabilities	19,936	27,570
Total current liabilities	27,435	39,385
Long term debt	76,800	75,700
Operating lease liabilities	8,744	8,888
Other liabilities	29	29
Total liabilities	113,008	124,002
Commitments and contingencies (Note 6)
Shareholders’ equity:
Ordinary shares: £0.002 nominal value: 152,500 shares authorized, 100,481,993 issued and outstanding at March 31, 2024: 152,500,000 shares authorized, 98,775 issued and outstanding at December 31, 2023	277	273
Additional paid-in capital	1,004,254	987,423
Accumulated other comprehensive loss	1,623	1,493
Accumulated deficit	(790,991)	(752,945)
Total shareholders’ equity	215,163	236,244
Total liabilities and shareholders' equity	$ 328,171	$ 360,246

About Centessa Pharmaceuticals Limited

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

CEO	Dr. Saurabh Saha M.D., Ph.D.
WEBSITE	centessa.com
INDUSTRY	Biotechnology
EMPLOYEES	64

Centessa Pharmaceuticals Limited Frequently Asked Questions

What is the ticker symbol for Centessa Pharmaceuticals Limited? What does CNTA stand for in stocks?

CNTA is the stock ticker symbol of Centessa Pharmaceuticals Limited. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Centessa Pharmaceuticals Limited (CNTA)?

As of Thu May 16 2024, market cap of Centessa Pharmaceuticals Limited is 1.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNTA stock?

You can check CNTA's fair value in chart for subscribers.

What is the fair value of CNTA stock?

You can check CNTA's fair value in chart for subscribers. The fair value of Centessa Pharmaceuticals Limited is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Centessa Pharmaceuticals Limited is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Centessa Pharmaceuticals Limited a good stock to buy?

The fair value guage provides a quick view whether CNTA is over valued or under valued. Whether Centessa Pharmaceuticals Limited is cheap or expensive depends on the assumptions which impact Centessa Pharmaceuticals Limited's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTA.

What is Centessa Pharmaceuticals Limited's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, CNTA's PE ratio (Price to Earnings) is -7.31 and Price to Sales (PS) ratio is 147.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNTA PE ratio will change depending on the future growth rate expectations of investors.